Psilocybin for the Treatment of Migraine Headache

The purpose of this study is to investigate the effects of oral psilocybin in migraine headache.

Subjects will each receive a dose of placebo and a dose of psilocybin approximately 14 days apart. Subjects will be randomized to the order of treatment and they will be randomized to receive either low or high dose psilocybin. Subjects will maintain a headache diary prior to, during, and after the treatments in order to document headache frequency and intensity, as well as associated symptoms.

This preliminary study will inform on the basic effects of psilocybin in migraine headache and inform on the design of larger, more definitive studies.

Topic Pain Headache Disorders
Compound Placebo Psilocybin
Country United States of America
Visit trial
Status Completed
Results Published No
Start date 11 January 2017
End date 01 June 2023
Chance of happening 100%
Phase Phase I
Design Blinded
Type Interventional
Generation First
Participants 24
Sex All
Age 21- 65
Therapy No

Trial Details

The purpose of this study is to investigate the effects of oral psilocybin in migraine headache. Subjects will each receive a dose of placebo and a dose of psilocybin approximately 14 days apart. Subjects will be randomized to the order of treatment and they will be randomized to receive either low or high dose psilocybin. Subjects will maintain a headache diary prior to, during, and after the treatments in order to document headache frequency and intensity, as well as associated symptoms. This preliminary study will inform on the basic effects of psilocybin in migraine headache and inform on the design of larger, more definitive studies.

NCT Number NCT03341689

Sponsors & Collaborators

Yale University
The Yale Psychedelic Science Group was established in 2016.

Papers

Exploratory Controlled Study of the Migraine-Suppressing Effects of Psilocybin
This double-blind, placebo-controlled, cross-over study (n=10) finds that a medium dose of psilocybin (10mg/70kg) significantly reduced migraines (headaches) in the two weeks after dosing.

Measures Used

5-Dimensional Altered States of Consciousness Questionnaire
The 5D-ASC scale measures altered states of consciousness and contains 94 items (visual analog scales).

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.